{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:54:54Z","timestamp":1793170494815,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increased airway NLRP3 inflammasome-mediated IL-1\u03b2 responses may underpin severe neutrophilic asthma. However, whether increased inflammasome activation is unique to severe asthma, is a common feature of immune cells in all inflammatory types of severe asthma, and whether inflammasome activation can be therapeutically targeted in patients, remains unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the activation and inhibition of inflammasome-mediated IL-1\u03b2 responses in immune cells from patients with asthma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Peripheral blood mononuclear cells (PBMCs) were isolated from patients with non-severe (<jats:italic>n<\/jats:italic>\u2009=\u200959) and severe (<jats:italic>n<\/jats:italic>\u2009=\u200936 stable, <jats:italic>n<\/jats:italic>\u2009=\u200917 exacerbating) asthma and healthy subjects (<jats:italic>n<\/jats:italic>\u2009=\u200939). PBMCs were stimulated with nigericin or lipopolysaccharide (LPS) alone, or in combination (LPS\u2009+\u2009nigericin), with or without the NLRP3 inhibitor MCC950, and the effects on IL-1\u03b2 release were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>PBMCs from patients with non-severe or severe asthma produced more IL-1\u03b2 in response to nigericin than those from healthy subjects. PBMCs from patients with severe asthma released more IL-1\u03b2 in response to LPS\u2009+\u2009nigericin than those from non-severe asthma. Inflammasome-induced IL-1\u03b2 release from PBMCs from patients with severe asthma was not increased during exacerbation compared to when stable. Inflammasome-induced IL-1\u03b2 release was not different between male and female, or obese and non-obese patients and correlated with eosinophil and neutrophil numbers in the airways. MCC950 effectively suppressed LPS-, nigericin-, and LPS\u2009+\u2009nigericin-induced IL-1\u03b2 release from PBMCs from all groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>An increased ability for inflammasome priming and\/or activation is a common feature of systemic immune cells in both severe and non-severe asthma, highlighting inflammasome inhibition as a universal therapy for different subtypes of disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-023-02603-2","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T02:01:23Z","timestamp":1701655283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Characterization and inhibition of inflammasome responses in severe and non-severe asthma"],"prefix":"10.1186","volume":"24","author":[{"given":"Jay C.","family":"Horvat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Augood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrick","family":"Dupre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshitha","family":"Gunawardhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma R.","family":"Mayall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole G.","family":"Hansbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avril A. B.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A. J.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Holliday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Hansbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"2603_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J"},{"key":"2603_CR2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","volume":"373","author":"PJ Barnes","year":"2009","unstructured":"Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373:1905\u201317.","journal-title":"Lancet"},{"key":"2603_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/thx.2010.137414","volume":"65","author":"LG Heaney","year":"2010","unstructured":"Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax. 2010;65:787\u201394.","journal-title":"Thorax"},{"key":"2603_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1183\/09031936.02.00232001","volume":"19","author":"P Godard","year":"2002","unstructured":"Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002;19:61\u20137.","journal-title":"Eur Respir J"},{"key":"2603_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2174\/138945010791591412","volume":"11","author":"W Wang","year":"2010","unstructured":"Wang W, Li JJ, Foster PS, Hansbro PM, Yang M. Potential therapeutic targets for steroid-resistant asthma. Curr Drug Targets. 2010;11:957\u201370.","journal-title":"Curr Drug Targets"},{"key":"2603_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/imr.12543","volume":"278","author":"PM Hansbro","year":"2017","unstructured":"Hansbro PM, Kim RY, Starkey MR, Donovan C, Dua K, Mayall JR, Liu G, Hansbro NG, Simpson JL, Wood LG, et al. Mechanisms and treatments for severe, steroid-resistant allergic airway disease and asthma. Immunol Rev. 2017;278:41\u201362.","journal-title":"Immunol Rev"},{"key":"2603_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1517\/13543784.2013.732997","volume":"22","author":"PM Hansbro","year":"2013","unstructured":"Hansbro PM, Scott GV, Essilfie AT, Kim RY, Starkey MR, Nguyen DH, Allen PD, Kaiko GE, Yang M, Horvat JC, Foster PS. Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opin Investig Drugs. 2013;22:49\u201369.","journal-title":"Expert Opin Investig Drugs"},{"key":"2603_CR8","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1378\/chest.07-1047","volume":"132","author":"DE Shaw","year":"2007","unstructured":"Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest. 2007;132:1871\u20135.","journal-title":"Chest"},{"key":"2603_CR9","doi-asserted-by":"publisher","first-page":"190096","DOI":"10.1183\/16000617.0096-2019","volume":"28","author":"R Wadhwa","year":"2019","unstructured":"Wadhwa R, Dua K, Adcock IM, Horvat JC, Kim RY, Hansbro PM. Cellular mechanisms underlying steroid-resistant asthma. Eur Respir Rev. 2019;28:190096.","journal-title":"Eur Respir Rev"},{"key":"2603_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/14728222.2020.1786535","volume":"24","author":"I Galvao","year":"2020","unstructured":"Galvao I, Kim RY, Shen S, Budden KF, Vieira AT, Hansbro PM. Emerging therapeutic targets and preclinical models for severe asthma. Expert Opin Ther Targets. 2020;24:845\u201357.","journal-title":"Expert Opin Ther Targets"},{"key":"2603_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40733-016-0029-3","volume":"3","author":"C Nunes","year":"2017","unstructured":"Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.","journal-title":"Asthma Res Pract"},{"key":"2603_CR12","doi-asserted-by":"publisher","first-page":"1700634","DOI":"10.1183\/13993003.00634-2017","volume":"49","author":"R Buhl","year":"2017","unstructured":"Buhl R, Humbert M, Bjermer L, Chanez P, Heaney Liam G, Pavord I, Quirce S, Virchow JC, Holgate S. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49:1700634.","journal-title":"Eur Respir J"},{"key":"2603_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","volume":"178","author":"P Haldar","year":"2008","unstructured":"Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218\u201324.","journal-title":"Am J Respir Crit Care Med"},{"key":"2603_CR14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.jaci.2016.08.048","volume":"139","author":"D Lefaudeux","year":"2017","unstructured":"Lefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F, Bansal AT, Lutter R, Sousa AR, Corfield J, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2017;139:1797\u2013807.","journal-title":"J Allergy Clin Immunol"},{"key":"2603_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","volume":"181","author":"WC Moore","year":"2010","unstructured":"Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D\u2019Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315\u201323.","journal-title":"Am J Respir Crit Care Med"},{"key":"2603_CR16","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jaci.2021.10.003","volume":"149","author":"JW Pinkerton","year":"2021","unstructured":"Pinkerton JW, Kim RY, Brown AC, Rae BE, Donovan C, Mayall JR, Carroll OR, Khadem Ali M, Scott HA, Berthon BS, et al. Relationship between type 2 cytokine and inflammasome responses in obesity-associated asthma. J Allergy Clin Immunol. 2021;149:1270\u201380.","journal-title":"J Allergy Clin Immunol"},{"key":"2603_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1586\/17512433.2016.1172208","volume":"9","author":"CL Grainge","year":"2016","unstructured":"Grainge CL, Maltby S, Gibson PG, Wark PA, McDonald VM. Targeted therapeutics for severe refractory asthma: monoclonal antibodies. Expert Rev Clin Pharmacol. 2016;9:927\u201341.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2603_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.anai.2022.04.020","volume":"129","author":"NM Niessen","year":"2022","unstructured":"Niessen NM, Fricker M, McDonald VM, Gibson PG. T2-low: what do we know?: Past, present, and future of biologic therapies in noneosinophilic asthma. Ann Allergy Asthma Immunol. 2022;129:150\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2603_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1183\/09031936.00105013","volume":"43","author":"JL Simpson","year":"2014","unstructured":"Simpson JL, Phipps S, Baines KJ, Oreo KM, Gunawardhana L, Gibson PG. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J. 2014;43:1067\u201376.","journal-title":"Eur Respir J"},{"issue":"153\u2013160","key":"2603_CR20","first-page":"160.e151","volume":"127","author":"KJ Baines","year":"2011","unstructured":"Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol. 2011;127(153\u2013160):160.e151-159.","journal-title":"J Allergy Clin Immunol"},{"key":"2603_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jmcb\/mjr042","volume":"4","author":"AG Besnard","year":"2012","unstructured":"Besnard AG, Togbe D, Couillin I, Tan Z, Zheng SG, Erard F, Le Bert M, Quesniaux V, Ryffel B. Inflammasome-IL-1-Th17 response in allergic lung inflammation. J Mol Cell Biol. 2012;4:3\u201310.","journal-title":"J Mol Cell Biol"},{"key":"2603_CR22","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jaci.2010.02.008","volume":"125","author":"AT Hastie","year":"2010","unstructured":"Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, Bleecker ER. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010;125:1028-1036.e1013.","journal-title":"J Allergy Clin Immunol"},{"key":"2603_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm.3423","volume":"20","author":"HY Kim","year":"2014","unstructured":"Kim HY, Lee HJ, Chang YJ, Pichavant M, Shore SA, Fitzgerald KA, Iwakura Y, Israel E, Bolger K, Faul J, et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med. 2014;20:54\u201361.","journal-title":"Nat Med"},{"key":"2603_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000237234","volume":"109","author":"S Konno","year":"1996","unstructured":"Konno S, Gonokami Y, Kurokawa M, Kawazu K, Asano K, Okamoto K, Adachi M. Cytokine concentrations in sputum of asthmatic patients. Int Arch Allergy Immunol. 1996;109:73\u20138.","journal-title":"Int Arch Allergy Immunol"},{"key":"2603_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1165\/ajrcmb.41.2.246","volume":"41","author":"AA Wanderer","year":"2009","unstructured":"Wanderer AA. Corticosteroid resistance in pulmonary neutrophilic inflammatory disorders and rationale for adjunct IL-1beta targeted therapy. Am J Respir Cell Mol Biol. 2009;41:246\u20137.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2603_CR26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jaci.2017.02.045","volume":"141","author":"C Rossios","year":"2018","unstructured":"Rossios C, Pavlidis S, Hoda U, Kuo CH, Wiegman C, Russell K, Sun K, Loza MJ, Baribaud F, Durham AL, et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. J Allergy Clin Immunol. 2018;141:560\u201370.","journal-title":"J Allergy Clin Immunol"},{"key":"2603_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1164\/rccm.201609-1830OC","volume":"196","author":"RY Kim","year":"2017","unstructured":"Kim RY, Pinkerton JW, Essilfie AT, Robertson AAB, Baines KJ, Brown AC, Mayall JR, Ali MK, Starkey MR, Hansbro NG, et al. Role for NLRP3 Inflammasome-mediated, IL-1beta-Dependent Responses in Severe, Steroid-Resistant Asthma. Am J Respir Crit Care Med. 2017;196:283\u201397.","journal-title":"Am J Respir Crit Care Med"},{"key":"2603_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1440-1843.2006.00784.x","volume":"11","author":"JL Simpson","year":"2006","unstructured":"Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11:54\u201361.","journal-title":"Respirology"},{"key":"2603_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2147\/JIR.S141220","volume":"11","author":"M Groslambert","year":"2018","unstructured":"Groslambert M, Py BF. Spotlight on the NLRP3 inflammasome pathway. J Inflamm Res. 2018;11:359\u201374.","journal-title":"J Inflamm Res"},{"key":"2603_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.molimm.2017.01.014","volume":"86","author":"JW Pinkerton","year":"2017","unstructured":"Pinkerton JW, Kim RY, Robertson AAB, Hirota JA, Wood LG, Knight DA, Cooper MA, O\u2019Neill LAJ, Horvat JC, Hansbro PM. Inflammasomes in the lung. Mol Immunol. 2017;86:44\u201355.","journal-title":"Mol Immunol"},{"key":"2603_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"K Schroder","year":"2010","unstructured":"Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821\u201332.","journal-title":"Cell"},{"key":"2603_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/thoraxjnl-2014-206736","volume":"70","author":"RY Kim","year":"2015","unstructured":"Kim RY, Pinkerton JW, Gibson PG, Cooper MA, Horvat JC, Hansbro PM. Inflammasomes in COPD and neutrophilic asthma. Thorax. 2015;70:1199\u2013201.","journal-title":"Thorax"},{"key":"2603_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417\u201326.","journal-title":"Mol Cell"},{"key":"2603_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"F Martinon","year":"2009","unstructured":"Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229\u201365.","journal-title":"Annu Rev Immunol"},{"key":"2603_CR35","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1172\/JCI40599","volume":"119","author":"A Stutz","year":"2009","unstructured":"Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. J Clin Invest. 2009;119:3502\u201311.","journal-title":"J Clin Invest"},{"key":"2603_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/ni.2913","volume":"15","author":"BS Franklin","year":"2014","unstructured":"Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, Brenker C, Nordhoff M, Mirandola SR, Al-Amoudi A, et al. The adaptor ASC has extracellular and \u201cprionoid\u201d activities that propagate inflammation. Nat Immunol. 2014;15:727\u201337.","journal-title":"Nat Immunol"},{"key":"2603_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.tim.2005.06.004","volume":"13","author":"TA Kufer","year":"2005","unstructured":"Kufer TA, Fritz JH, Philpott DJ. NACHT-LRR proteins (NLRs) in bacterial infection and immunity. Trends Microbiol. 2005;13:381\u20138.","journal-title":"Trends Microbiol"},{"key":"2603_CR38","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.4049\/jimmunol.1402658","volume":"194","author":"MA Katsnelson","year":"2015","unstructured":"Katsnelson MA, Rucker LG, Russo HM, Dubyak GR. K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J Immunol. 2015;194:3937\u201352.","journal-title":"J Immunol"},{"key":"2603_CR39","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1398-9995.2011.02586.x","volume":"66","author":"A-G Besnard","year":"2011","unstructured":"Besnard A-G, Guillou N, Tschopp J, Erard F, Couillin I, Iwakura Y, Quesniaux V, Ryffel B, Togbe D. NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant. Allergy. 2011;66:1047\u201357.","journal-title":"Allergy"},{"key":"2603_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4049\/jimmunol.181.1.17","volume":"181","author":"H Li","year":"2008","unstructured":"Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum\u2019s adjuvant effect are mediated by NLRP3. J Immunol. 2008;181:17\u201321.","journal-title":"J Immunol"},{"key":"2603_CR41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/02770900500308387","volume":"42","author":"L Rhodes","year":"2005","unstructured":"Rhodes L, Moorman JE, Redd SC. Sex differences in asthma prevalence and other disease characteristics in eight states. J Asthma. 2005;42:777\u201382.","journal-title":"J Asthma"},{"key":"2603_CR42","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1183\/09031936.03.00261903","volume":"22","author":"Group TES","year":"2003","unstructured":"Group TES. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J. 2003;22:470\u20137.","journal-title":"Eur Respir J"},{"key":"2603_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2021.738987","volume":"2","author":"J Ackland","year":"2021","unstructured":"Ackland J, Watson A, Wilkinson TMA, Staples KJ. Interrupting the conversation: implications for crosstalk between viral and bacterial infections in the asthmatic airway. Front Allergy. 2021;2: 738987.","journal-title":"Front Allergy"},{"key":"2603_CR44","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/thoraxjnl-2014-206067","volume":"70","author":"AT Essilfie","year":"2015","unstructured":"Essilfie AT, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Beckett EL, Starkey MR, Simpson JL, Foster PS, Gibson PG, Hansbro PM. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax. 2015;70:458\u201367.","journal-title":"Thorax"},{"key":"2603_CR45","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaci.2016.04.038","volume":"139","author":"RY Kim","year":"2017","unstructured":"Kim RY, Horvat JC, Pinkerton JW, Starkey MR, Essilfie AT, Mayall JR, Nair PM, Hansbro NG, Jones B, Haw TJ, et al. MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2. J Allergy Clin Immunol. 2017;139:519\u201332.","journal-title":"J Allergy Clin Immunol"},{"key":"2603_CR46","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1164\/rccm.202110-2389CI","volume":"205","author":"W Cookson","year":"2022","unstructured":"Cookson W, Moffatt M, Rapeport G, Quint J. A pandemic lesson for global lung diseases: exacerbations are preventable. Am J Respir Crit Care Med. 2022;205:1271\u201380.","journal-title":"Am J Respir Crit Care Med"},{"key":"2603_CR47","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1164\/rccm.202201-0129OC","volume":"206","author":"PJ McDowell","year":"2022","unstructured":"McDowell PJ, Busby J, Hanratty CE, Djukanovic R, Woodcock A, Walker S, Hardman TC, Arron JR, Choy DF, Bradding P, et al. Exacerbation profile and risk factors in a type-2-low enriched severe asthma cohort: a clinical trial to assess asthma exacerbation phenotypes. Am J Respir Crit Care Med. 2022;206:545\u201353.","journal-title":"Am J Respir Crit Care Med"},{"key":"2603_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12931-017-0524-y","volume":"18","author":"SF Seys","year":"2017","unstructured":"Seys SF, Scheers H, Van den Brande P, Marijsse G, Dilissen E, Van Den Bergh A, Goeminne PC, Hellings PW, Ceuppens JL, Dupont LJ, Bullens DM. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respir Res. 2017;18:39.","journal-title":"Respir Res"},{"key":"2603_CR49","doi-asserted-by":"publisher","first-page":"2102669","DOI":"10.1183\/13993003.02669-2021","volume":"59","author":"SF Seys","year":"2022","unstructured":"Seys SF, Long MB. The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm. Eur Respir J. 2022;59:2102669.","journal-title":"Eur Respir J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02603-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02603-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02603-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T14:05:10Z","timestamp":1701698710000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02603-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2603"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02603-2","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]},"assertion":[{"value":"13 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed with approval from the Hunter Area Health Service (2019\/ETH01030) and University of Newcastle Human Research Ethics Committee (H-2017-0088). All participants gave written informed consent before their inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None of the authors have a conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"303"}}